AA
TCRR

AlphaCentric Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

AlphaCentric Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-151,000
Closed -$272K – 221
2022
Q3 		$272K Buy
+151,000
New +$438K 0.28% 81
2021
Q4 		$704K Buy
151,000
+38,000
+34% +$238K 0.21% 48
2021
Q3 		$962K Buy
113,000
+72,000
+176% +$1.02M 0.24% 33
2021
Q2 		$673K Buy
41,000
+35,500
+645% +$717K 0.18% 43
2021
Q1 		$121K Buy
5,500
+3,225
+142% +$87.9K 0.04% 128
2020
Q4 		$70K Buy
2,275
+375
+20% +$9.48K 0.03% 164
2020
Q3 		$39K Buy
+1,900
New +$33.4K 0.02% 122

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AlphaCentric Advisors's TCRR Position: Q4 2022 in Review

AlphaCentric Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 151,000 shares — an estimated $272K sold.

AlphaCentric Advisors first reported a position in TCRR in Q3 2020 and held it in 7 quarters. The position peaked at $962K in Q3 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • AlphaCentric Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • AlphaCentric Advisors sold 151,000 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $272K.
  • AlphaCentric Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • AlphaCentric Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $962K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on AlphaCentric Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.